RBMX

Across TCGA pan-cancer cohorts, RBMX Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RBMX data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher RBMX Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBMX expression acts as an unfavorable survival marker.

CHOL, LIHC, and BLCA are the cancer types where RBMX Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Median	All	0.045	0.486	.009	15	view →
LIHC	DFS	Median	All	0.045	0.553	<.001	12	view →
BLCA	OS	Median	IV	0.132	0.599	.004	6	view →
SKCM	OS	Median	All	0.420	0.783	.032	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RBMX–CHOL (DFS)

Open the CHOL breakdown →